BPBelén Pimentel

Belén Pimentel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Belén Pimentel has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Five-Year Cardiorenal Outcomes and Longitudinal Chronic Kidney Disease Screening in People with Type 2 Diabetes Managed by Endocrinologists: A Nationwide Retrospective Cohort Study

    by José Ignacio Martínez-Montoro, José Juan Aparicio-Sánchez, Belén Pimentel, Mónica Juárez-Campo, Maria Luisa Alamillo, Yesika Díaz, José Carlos Fernández-García

    Background/Objectives: Type 2 diabetes (T2D) is a major risk factor for cardiovascular disease and chronic kidney disease (CKD), yet the extent of longitudinal CKD screening in routine clinical practice remains unclear. This study aimed to assess long-term cardiorenal outcomes and CKD screening practices in patients with T2D managed across primary care and endocrinology settings, evaluating the feasibility of risk stratification in real-world practice. Methods: We conducted a retrospective cohort study using anonymized data from the Telotrón database (2.2 million patients). Adults with T2D attended across primary and endocrinology care were followed from 1 January 2018 to 31 December 2022. Frequency of estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) measurements, and cumulative proportion of kidney and cardiovascular events, hospitalizations, and mortality were assessed. Results: Among 13,600 individuals, 31.1% experienced a kidney event and 18.6% a cardiovascular event over 5 years. All-cause hospitalization occurred in 24.9% and 16.1% died. First occurrence of an abnormal eGFR or UACR measurement occurred in 37.0% of participants without baseline CKD, and 45.4% with baseline CKD showed progression. Annual monitoring was limited, with 39.1% and 16.6% undergoing at least one yearly assessment, and 2.9 and 1.5 mean number of measurements per patient for eGFR and UACR, respectively. Conclusions: Despite receiving endocrinology care, kidney disease progression and cardiovascular events remain a major concern in T2D, and yet suboptimal albuminuria and eGFR assessment limit early detection and risk stratification, thereby hindering risk-directed management.

  • Open Access

    Natural Language Processing of Unstructured Healthcare Data for Predicting Heart Failure in Individuals with Type 2 Diabetes

    by Juan F. Navarro-González, Leopoldo Pérez de Isla, Gloria Cánovas Molina, Miguel Ángel Brito-Sanfiel, David Emilio Barajas Galindo, Luis Ángel Cuellar Olmedo, Dídac Mauricio, Santiago Tofé Povedano, José Antonio Balsa Barro, Matilde Rubio Almanza, et al.

    Background/Objectives: Type 2 diabetes mellitus (T2DM) is a multisystemic disease with overlapping metabolic, renal, and cardiovascular effects. Within the Diabetic@ project, which aims to characterize individuals with T2DM using real-world data extracted from electronic health records (EHRs), this substudy sought to develop a predictive model for two-year heart failure (HF) risk. Methods: Multicenter, retrospective study including T2DM individuals across eight Spanish hospitals (2013–2018). Data were extracted exclusively from EHRs’ unstructured free text using clinical natural language processing (cNLP) and mapped to SNOMED CT. At inclusion, individuals were categorized as having or not prevalent HF (pHF). Predictive modeling was performed in non-pHF to assess two-year risk of developing HF, termed incident HF (iHF). Logistic regression (LR), decision trees, random forest, and XGBoost were compared, selecting for accuracy and interpretability. Results: Of 588,756 individuals with T2DM, 84,197 (14.3%) had pHF. Among non-pHF, 353,371 (60%) were used for model development (90.7% training, 9.3% validation). iHF occurred in 13.6% of the training set and 11.4% of the validation set. Ischemic heart disease was present in 16.2% overall, 37.9% in pHF, and 12.6% in non-pHF. Glycosylated hemoglobin data was rarely reported (<15%). LR achieved the best performance (AUC-ROC 0.73) using 27 predictors. Reduced 12- and clinically refined 9-predictor models performed similarly, with the latter implemented in a web-based tool. Conclusions: Unstructured data from EHRs enabled development of a two-year HF risk model for individuals with T2DM, underscoring the potential of cNLP for risk stratification across the cardiovascular–renal–metabolic spectrum.


  • Open Access

    Screening, prevalence, and burden of chronic kidney disease in people with type 2 diabetes managed by endocrinologists: A nationwide cross-sectional study

    by José Ignacio Martínez-Montoro, Jose Juan Aparicio-Sánchez, Belén Pimentel, Mónica Juárez-Campo, María Luisa Alamillo, José Carlos Fernández-García


  • Targeted Cancer Cell Killing by Highly Selective miRNA-Triggered Activation of a Prokaryotic Toxin–Antitoxin System

    by Alice Turnbull, Camino Bermejo-Rodríguez, Mark A. Preston, María Garrido-Barros, Belén Pimentel, Guillermo de la Cueva-Méndez

    Although not evolved to function in eukaryotes, prokaryotic toxin Kid induces apoptosis in human cells, and this is avoided by coexpression of its neutralizing antitoxin, Kis. Inspired by the way Kid becomes active in bacterial cells we had previously engineered a synthetic toxin–antitoxin system bearing a Kis protein variant that is selectively degraded in cells expressing viral oncoprotein E6, thus achieving highly selective killing of cancer cells transformed by human papillomavirus. Here we aimed to broaden the type of oncogenic insults, and therefore of cancer cells, that can be targeted using this approach. We show that appropriate linkage of the kis gene to a single, fully complementary, target site for an oncogenic human microRNA enables the construction of a synthetic toxin–antitoxin pair that selectively kills cancer cells overexpressing that particular microRNA. Importantly, the resulting system spares nontargeted cells from collateral damage, even when they overexpress highly homologous, though nontargeted, microRNAs.


  • Open Access

    Targeted cancer cell killing by highly selective miRNA-triggered activation of a prokaryotic toxin-antitoxin system

    by Alice Turnbull, Camino Bermejo-Rodríguez, Mark A. Preston, María Garrido-Barros, Belén Pimentel, Guillermo de la Cueva-Méndez

    Although not evolved to function in eukaryotes, prokaryotic toxin Kid induces apoptosis in human cells, and this is avoided by co-expression of its neutralizing antitoxin, Kis. Inspired by the way Kid becomes active in bacterial cells we had previously engineered a synthetic toxin-antitoxin system bearing a Kis protein variant that is selectively degraded in cells expressing viral oncoprotein E6, thus achieving highly selective killing of cancer cells transformed by human papillomavirus. Here we aimed to broaden the type of oncogenic insults, and therefore of cancer cells, that can be targeted using this approach. We show that appropriate linkage of the kis gene to a single, fully complementary, target site for an oncogenic human microRNA enables the construction of a synthetic toxin-antitoxin pair that selectively kills cancer cells overexpressing that particular microRNA. Importantly, the resulting system spares non-targeted cells from collateral damage, even when they overexpress highly homologous, though non-targeted, microRNAs.


  • ‘Smartening’ anticancer therapeutic nanosystems using biomolecules

    by Rebeca Núñez-Lozano, Manuel Cano, Belén Pimentel, Guillermo de la Cueva-Méndez


  • Repurposing a Prokaryotic Toxin-Antitoxin System for the Selective Killing of Oncogenically Stressed Human Cells

    by Mark A. Preston, Belén Pimentel, Camino Bermejo-Rodríguez, Isabelle Dionne, Alice Turnbull, Guillermo de la Cueva-Méndez

    Prokaryotes express intracellular toxins that pass unnoticed to carrying cells until coexpressed antitoxin partners are degraded in response to stress. Although not evolved to function in eukaryotes, one of these toxins, Kid, induces apoptosis in mammalian cells, an effect that is neutralized by its cognate antitoxin, Kis. Here we engineered this toxin-antitoxin pair to create a synthetic system that becomes active in human cells suffering a specific oncogenic stress. Inspired by the way Kid becomes active in bacterial cells, we produced a Kis variant that is selectively degraded in human cells expressing oncoprotein E6. The resulting toxin-antitoxin system functions autonomously in human cells, distinguishing those that suffer the oncogenic insult, which are killed by Kid, from those that do not, which remain protected by Kis. Our results provide a framework for developing personalized anticancer strategies avoiding off-target effects, a challenge that has been hardly tractable by other means thus far.


  • Open Access

    Biocompatible Films with Tailored Spectral Response for Prevention of DNA Damage in Skin Cells

    by Rebeca Núñez‐Lozano, Belén Pimentel, José R. Castro‐Smirnov, Mauricio E. Calvo, Hernán Míguez, Guillermo de la Cueva‐Méndez

    A hybrid nanostructured organic–in­organic biocompatible film capable of efficiently blocking a preselected range of ultraviolet light is designed to match the genotoxic action spectrum of human epithelial cells. This stack protects cultured human skin cells from UV-induced DNA lesions. As the shielding mechanism relies exclusively on reflection, the secondary effects due to absorption harmful radiation are prevented.


  • Toxin Kid uncouples DNA replication and cell division to enforce retention of plasmid R1 in Escherichia coli cells

    by Belén Pimentel, Radhika Nair, Camino Bermejo-Rodríguez, Mark A. Preston, Chukwuma A. Agu, Xindan Wang, Juan A. Bernal, David J. Sherratt, Guillermo de la Cueva-Méndez

    Significance: Many plasmids disseminating antibiotic resistance in bacteria encode toxin-antitoxin (TA) pairs, which are generally assumed to function as postsegregational killing (PSK) systems. A shortage of antibiotic alternatives and the link of TA pairs to PSK have stimulated the opinion that premature toxin activation could be used to kill these recalcitrant organisms in the clinic. Following previous observations, we confirm here that toxin Kid (killing determinant) and antitoxin Kis (killing suppressor) function as a rescue system that enforces the retention of plasmid R1 by host cells, and not as a PSK system. Because the rescue system is conserved in clinically worrisome plasmids, our findings advise against the activation of this TA pair as an antibiotic strategy to fight pathogens carrying these extrachromosomal DNAs.


  • Open Access

    Gene and cell survival: lessons from prokaryotic plasmid R1

    by Guillermo de la Cueva‐Méndez, Belén Pimentel

    Plasmids are units of extrachromosomal genetic inheritance found in all kingdoms of life. They replicate autonomously and undergo stable propagation in their hosts. Despite their small size, plasmid replication and gene expression constitute a metabolic burden that compromises their stable maintenance in host cells. This pressure has driven the evolution of strategies to increase plasmid stability—a process accelerated by the ability of plasmids to transfer horizontally between cells and to exchange genetic material with their host and other resident episomal DNAs. These abilities drive the adaptability and diversity of plasmids and their host cells. Indeed, survival functions found in plasmids have chromosomal homologues that have an essential role in cellular responses to stress. An analysis of these functions in the prokaryotic plasmid R1, and of their intricate interrelationships, reveals remarkable overall similarities with other gene‐ and cell‐survival strategies found within and beyond the prokaryotic world.